🇺🇸 FDA

Company profile · Sponsor

Taiho

Taiho Pharma Netherlands B.V.

E6E807A · EMA pharma EU
Pipeline
13
Drugs
0
Patents
0

Quick answer

Taiho (E6E807A) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E6E807A
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (13)

Search pipeline →

  1. Azacitidine, Cedazuridine, Azacitidine, Vidaza 25 mg/ml powder for suspension for injection, Azacitidine, Cedazuridine

    Taiho

    Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)

    phase 3 small molecule active

    1 trial

  2. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion

    Taiho

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial

  3. Futibatinib, FULVESTRANT

    Taiho

    Malignant Solid Tumors

    phase 3 small molecule active

    1 trial

  4. Zipalertinib Placebo Tablets is a film-coated tablet that does not contain the active ingredient, zipalertinib., Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Taiho

    Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations

    phase 3 small molecule active

    1 trial

  5. ASTX727

    Taiho

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors

    phase 2 small molecule active

    1 trial

  6. ASTX727, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    Taiho

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  7. CAMPTO 20 mg/mL concentrate for solution for infusion, Futibatinib, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, FLUOROURACIL, CISPLATIN, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho

    Solid Tumors

    phase 2 small molecule active

    1 trial

  8. Futibatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho

    Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  9. Tolinapant, Tolinapant

    Taiho

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

  10. A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors

    Taiho

    Locally Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  11. ASTX727, ASTX727, Decitabine, ASTX727

    Taiho

    Myelodysplastic Syndromes (MDS)

    phase 1 small molecule active

    1 trial

  12. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment

    Taiho

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  13. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment

    Taiho

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is Taiho?

Taiho (E6E807A) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Taiho sponsor?

We track 13 ClinicalTrials.gov-linked programs for Taiho, including Azacitidine, Cedazuridine, Azacitidine, Vidaza 25 mg/ml powder for suspension for injection, Azacitidine, Cedazuridine and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Taiho company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.